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Adjuvant therapy 
after resection of 
brain metastases
Frameless image-guided LINAC-based 
radiosurgery and stereotactic 
hypofractionated radiotherapy
Up until now, whole-brain radiation ther-
apy (WBRT) has been the standard adju-
vant therapy following resection of brain 
metastases, since it decreases the rate of 
local and distant recurrence in the brain 
[16]. WBRT with the addition of a boost 
to the resection cavity has been shown 
to increase local control (LC) rates. Since 
no survival benefit has been demonstrat-
ed for WBRT in addition to surgery or 
SRS, there is interest avoiding the poten-
tial neurocognitive sequelae associated 
with this treatment [12]. Recently, sever-
al retrospective reports have demonstrat-
ed that stereotactic radiosurgery (SRS) or 
stereotactic hypofractionated radiothera-
py (SHRT) directed at the resection cavity 
can reduce local failure rates [19, 25]. Most 
patients were treated with frame-based 
stereotactic systems such as the Gam-
ma Knife (Elekta, Stockholm, Sweden) or 
dedicated stereotactic LINAC systems [7, 
10, 15]. Frameless image-guided intracra-
nial stereotactic LINAC radiosurgery for 
brain metastases has recently been intro-
duced and clinical outcomes are compa-
rable to those after frame-based radiosur-
gery techniques [4, 11]. Here we report on 
clinical outcome and LC in patients who 
underwent adjuvant frameless image-
guided LINAC-based SRS and SHRT af-
ter resection of brain metastases.
Materials and methods
Patients and study design
This retrospective study was approved 
by the local ethics committee. Between 
March 2009 and February 2012, 44 surgi-
cal cavities in 42 patients were treated with 
frame less image-guided LINAC-based 
SRS or SHRT. Of these patients, 35 had 
total gross resection of the metastasis, 
which was confirmed by MRI within 24 h 
after surgery. Patients with one or two fur-
ther brain metastases were included and 
treated by SRS. Patients with prior WBRT 
were excluded. For each patient, the Ra-
diation Therapy Oncology Group recur-
sive partitioning analysis (RTOG RPA) 
classification and Graded Prognostic As-
sessment (GPA) scores were calculated 
[24]. Acute and late toxicities were eval-
uated using the Common Toxicity Crite-
ria for Adverse Events (CTCAE) version 
4.0 grading system. Clinical status evalu-
ation and imaging examinations were per-
formed at 3–6-month intervals. To assess 
local recurrence, new distant brain metas-
tases and radionecrosis, all posttreatment 
MRIs were reviewed by a radiation oncol-
ogist, a neuroradiologist and a neurosur-
geon. Radionecrosis was scored according 
to Late Effects in Normal Tissue—Subjec-
tive, Objective, Management and Analytic 
(LENT-SOMA) criteria [20].
Frameless SRS and 
SHRT procedures
All patients were immobilized using a 
thermoplastic stereotactic frameless head 
mask (BrainLAB, Feldkirchen, Germa-
ny). Postoperative helical CT images of 
1.5-mm slice thickness were obtained and 
fused with postoperative T1 contrast-en-
hanced MPRAGE and T2-3D sequenc-
es that were not older than 2 weeks pri-
or to irradiation. The clinical target vol-
ume (CTV) was defined as the resection 
cavity including the surgical defect and 
any contrast enhancement, plus a 2-mm 
margin in all directions. For definition of 
planning target volume (PTV), a 1-mm 
margin was added to the CTV in all di-
rections. Planning was carried out using 
the BrainLAB® iPlan planning system ver-
sions  4.1 and 4.5 (BrainLAB). All patients 
were irradiated with a single isocenter. 
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Dose–volume histograms (DVH) were 
calculated for the target volumes and or-
gans at risk. We used a conformity index 
(CI) defined according the following for-
mula: (1+ volume of tissue outside PTV 
receiving at least the prescribed dose/vol-
ume of PTV receiving at least the pre-
scribed dose). For SRS planning we eval-
uated the normal brain volume irradiated 
with 12 Gy (V12 Gy) or 10 Gy (V10 Gy), ac-
cording to previously published reports 
[3, 13]. For SHRT planning we evaluat-
ed the volume of normal brain irradiated 
with more than 4 Gy (V4 Gy) per fraction 
[8]. The prescribed SRS dose range was 
17–18 Gy for PTVs with a volume ≤10 cm3. 
Dose was prescribed in order to cover at 
least 95% of the PTV. For larger cavities, 
the dose concepts of SHRT were 4×6 Gy, 
6×4 Gy and 10×4 Gy. The fractionation 
scheme of 4×6 Gy was used for smaller 
PTVs with a volume ≤20 cm3. Initially, 
the dose concept of 6×4 Gy was used for 
 PTVs >20 cm3, but in order to increase the 
equivalent dose in 2-Gy fractions (EQD2), 
40 Gy was applied in 10 fractions. All 
treatments were delivered using the No-
valis TX® LINAC  (Varian Medical Systems 
Inc., Palo Alto, CA, USA and BrainLAB) 
in the 6-MV stereotactic mode. Patient 
setup was performed using the ExacTrac 
system (BrainLAB). ExacTrac delivers the 
patient setup error in six dimensions. In 
this study, the tolerances for the patient 
setup were 0.8 mm for the three transla-
tional axes (longitudinal, lateral and ver-
tical) and 1.0° for the three rotational axes 
(pitch, roll and couch rotation).
Treatment was delivered using con-
formal dynamic arcs, intensity-modulat-
ed radiation therapy (IMRT) field tech-
niques and hybrid arcs (dynamic arcs and 
IMRT fields).
Statistics
The analyzed endpoints were LC, dis-
tant brain control (DC) and overall sur-
vival (OS). LC was defined as the ab-
sence of new nodular contrast enhance-
ment adjacent to the resection cavity on 
MRI. Local recurrence (LR) was defined 
as new contrast-enhancing lesions with-
in 3 mm of the resection cavity, i.e. with-
in the PTV. New distant brain metastases 
were defined as new contrast-enhancing 
lesions outside the PTV. All time-to-event 
endpoints were measured from the begin-
ning of radiotherapy to either the last fol-
low-up MRI (for recurrence rates), the be-
ginning of salvage radiotherapy (for sal-
vage therapy) or the date of death for OS. 
Survival rates were calculated using the 
Kaplan–Meier product limit methodolo-
gy. Comparison of survival rates accord-
ing to treatment (SRS vs. SHRT) was per-
formed using a two-sided log-rank test. 
All ana lyses were conducted using SPSS 
version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Patient characteristics are shown in 
. Tab. 1. In 7 patients (16%) the postop-
erative MRI showed residual tumor af-
ter resection. At the time of irradiation, 
Tab. 1 Patient characteristics
Patient characteristic Finding
Median age in years (range) 67 (40–79)
Gender
– Female 19
– Male 23
KPS median (range) 80 (60–100)
Primary tumor
– NSCLC 19 (45%)
– Melanoma 9 (21%)
– GI cancer 6 (14%)
– Breast cancer 5 (12%)
– Gynecological cancer 2 (5%)
– CUP 1 (3%)
RPA classification
– 1 13 (31%)
– 2 25 (60%)
– 3 4 (9%)
GPA score
– 0–1 6 (14%)
– 1.5–2.5 26 (62%)
– 3.0–4.0 10 (24%)
Single BM 16 (38%)
Solitary BM 17 (40%)
2–3 BM 9 (22%)
Synchr./metachr. BM 10/32 (24/76%)
SRS 23 cavities
– PTV (median and range) 11 cm3 (2–17 cm3)
– CI median (range) 1.29 (1.02–1.7)
– CI mean (SD) 1.31 (0.18)
SHRT 21 cavities
– PTV (median and range) 22 cm3 (14–44 cm3)
– CI median (range) 1.2 (1.05–1.7)
– CI mean (SD) 1.2 (0.17)
– Fractionation 6×4 Gy 6/29%
 4×6 Gy 5/24%
 10×4 Gy 10/47%
KPS Karnofsky Performance Score, NSCLC non-small cell lung cancer, GI gastrointestinal, CUP cancer of 
unknown primary origin, RPA recursive partitioning analysis, GPA Graded Prognostic Assessment, BM brain 
metastases, Single BM only one BM but other sites of distant disease, solitary BM one BM as sole site of distant 
disease, synchr. BM synchronous BM detected during primary staging, metachr. BM metachronous BM de-
tected during restaging, SRS stereotactic radiosurgery, SHRT stereotactic hypofractionated radiotherapy, PTV 
planning target volume, CI conformity index, SD standard deviation.
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extracranial disease was present in 60% 
of patients. The median time from sur-
gery to irradiation was 40 days (range 15–
73 days).
Treatment parameters
Of the 44 surgical cavities in the 42 pa-
tients in the current study, 23 lesions 
(52%) were treated with SRS. The medi-
an dose prescription to the PTV margin 
was 17 Gy (range 16–18 Gy) with maxi-
mum and minimum median PTV doses 
of 17.7 Gy (range 17–20.4 Gy) and 16.8 Gy 
(range 14.6–18 Gy), respectively. One pa-
tient received 16 Gy to the PTV margin 
because the lesion was near critical struc-
tures. The median V10 Gy and V12 Gy values 
were 24.3 cm3 (range 0.6–45.0 cm3) and 
18.0 cm3 (range 0.4–28.9 cm3), respec-
tively. The median PTV for SHRT was 
22.3 cm3; the V4 Gy/fraction was 5.9 cm3. 
Mean patient setup errors for SRS and 
SHRT are summarized in . Tab. 4.
Local and distant brain control
The median follow-up was 9.6 months 
(range 0.9–27.4 months). The medi-
an follow-up of living patients (23) was 
10.8 months (range 2.4–27.4 months). 
Radiological follow-up data were not 
available for 4 patients. Median time to 
local brain recurrence was 7.3 months 
(range 3.5–9 months). Median time to 
any intracranial failure (local or distant) 
was 5.9 months. LC rates after 6 and 
12 months were 91 and 77%, respective-
ly. No statistically significant difference 
in LC rates between the SRS and SHRT 
treatments was observed (. Fig. 1). A 
total of 4 patients presented local recur-
rence: 1 patient after SRS treatment with 
17 Gy and 3 patients after SHRT treatment 
with 4×6 Gy, 6×4 Gy and 10×4 Gy. Details 
of patients with local recurrence are sum-
marized in . Tab. 2. Of the 7 patients 
with residual tumor after surgery, 6 pre-
sented no local recurrence; radiological 
follow-up data were not available for 1 pa-
tient. DBC rates at 6 and 12 months were 
61 and 33%, respectively. A total of 23 pa-
tients (61%) developed brain metastases 
at new sites during the follow-up peri-
od. Tumor growth along the surgical ac-
cess route was observed in 2 patients, sug-
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Adjuvant therapy after resection of brain metastases. 
Frameless image-guided LINAC-based radiosurgery 
and stereotactic hypofractionated radiotherapy
Abstract
Background. Tumor bed stereotactic ra-
diosurgery (SRS) after resection of brain me-
tastases is a new strategy to delay or avoid 
whole-brain irradiation (WBRT) and its asso-
ciated toxicities. This retrospective study ana-
lyzes results of frameless image-guided linear 
accelerator (LINAC)-based SRS and stereotac-
tic hypofractionated radiotherapy (SHRT) as 
adjuvant treatment without WBRT.
Materials and methods. Between March 
2009 and February 2012, 44 resection cavities 
in 42 patients were treated with SRS (23 cav-
ities) or SHRT (21 cavities). All treatments 
were delivered using a stereotactic LINAC. All 
cavities were expanded by ≥2 mm in all di-
rections to create the clinical target volume 
(CTV).
Results. The median planning target vol-
ume (PTV) for SRS was 11.1 cm3. The me-
dian dose prescribed to the PTV margin for 
SRS was 17 Gy. Median PTV for SHRT was 
22.3 cm3. The fractionation schemes ap-
plied were: 4 fractions of 6 Gy (5 patients), 
6 fractions of 4 Gy (6 patients) and 10 frac-
tions of 4 Gy (10 patients). Median follow-up 
was 9.6 months. Local control (LC) rates after 
6 and 12 months were 91 and 77%, respec-
tively. No statistically significant differenc-
es in LC rates between SRS and SHRT treat-
ments were observed. Distant brain control 
(DBC) rates at 6 and 12 months were 61 and 
33%, respectively. Overall survival (OS) at 
6 and 12 months was 87 and 63.5%, respec-
tively, with a median OS of 15.9 months. One 
patient treated by SRS showed symptoms of 
radionecrosis, which was confirmed histo-
logically.
Conclusion. Frameless image-guided LINAC- 
based adjuvant SRS and SHRT are effective 
and well tolerated local treatment strategies 
after resection of brain metastases in patients 
with oligometastatic disease.
Keywords
Toxicity · Metastases · Survival · Organs at 
risk · Quality of life
Adjuvante Therapie nach Resektion von Hirnmetastasen. 
Rahmenlose bildgesteuerte LINAC-basierte Radiochirurgie 
und stereotaktische hypofraktionierte Strahlentherapie
Zusammenfassung
Hintergrund. Stereotaktische Radiochirur-
gie (SRS) des Tumorbettes nach Resektion 
von Hirnmetastasen ist eine neuartige Stra-
tegie, um eine adjuvante Ganzhirnbestrah-
lung (WBRT) mit ihren Toxizitäten aufzu-
schieben oder zu vermeiden. Die vorliegen-
de Studie untersucht retrospektiv die Resul-
tate rahmenloser bildgesteuerter SRS und 
stereotaktischer hypofraktionierter Radio-
therapie (SHRT) als adjuvante Behandlung 
ohne WBRT.
Material und Methoden. Zwischen März 
2009 und Februar 2012 wurden 44 Resek-
tionshöhlen von 42 Patienten mit SRS (23 Ka-
vitäten) oder SHRT (21 Kavitäten) bestrahlt. 
Alle Behandlungen wurden mit einem ste-
reotaktischen Linearbeschleuniger durchge-
führt. Alle Kavitäten wurden um ≥2 mm zum 
klinischen Zielvolumen vergrößert.
Ergebnisse. Das mediane Planungsziel-
volumen (PTV) für SRS betrug 11,1 cm3. Die 
mediane Verschreibungsdosis für SRS auf 
den Rand des PTV lag bei 17 Gy. Das medi-
ane PTV für SHRT ergab 22,3 cm3. Es wur-
den Fraktio nierungen von 4-mal 6 Gy (5 Pa-
tienten), 6-mal 4 Gy (6 Patienten) und 10-mal 
4 Gy (10 Patienten) eingesetzt. Die mediane 
Nachkontrolldauer betrug 9,6 Monate. Die lo-
kale Kontrollrate nach 6 und 12 Mona ten be-
trug 91 bzw. 77%. Es wurde kein statistisch 
signifikanter Unterschied der lokalen Kon-
trolle zwischen SRS und SHRT festgestellt. Die 
Kontrollraten bezüglich weiterer zerebraler 
Metastasen nach 6 und 12 Monaten waren 
61 bzw. 33%. Das Gesamtüberleben nach 
6 und 12 Monaten lag bei 87 bzw. 63,5%, 
mit einem medianen Gesamtüberleben von 
15,9 Monaten. Eine symptomatische und his-
tologisch gesicherte Radionekrose zeigte sich 
bei einer Patientin, die mit SRS behandelt 
worden war.
Schlussfolgerungen. Rahmenlose bildge-
steuerte adjuvante SRS und SHRT mit einem 
Linearbeschleuniger sind wirksame und gut 
verträgliche lokale Behandlungen nach Re-
sektion von Hirnmetastasen in oligometas-
tatischen Patienten.
Schlüsselwörter
Toxizität · Metastasen · Überleben ·  
Risikoorgane · Lebensqualität
767Strahlentherapie und Onkologie 9 · 2013  | 
gestive of leptomeningeal seeding. Medi-
an survival after regional recurrence was 
6.4 months. OS at 6 and 12 months was 
87 and 63.5%, respectively, with a median 
OS of 15.9 months (. Fig. 2). At the last 
follow-up, 19 of the 42 patients had passed 
away. Salvage radiotherapy was applied 
in 16 patients (38%), 15 patients received 
WBRT and 1 patient was treated using ra-
diosurgery. The median estimated time to 
salvage irradiation was 13.4 months.
Toxicity
Symptomatic and pathologically proven 
radionecrosis occurred in 1 patient treated 
by SRS. This patient received a single dose 
of 17 Gy. The PTV, V12 Gy and V10 Gy values 
were 13.3 cm3, 21.5 cm3 and 29.6 cm3, re-
spectively. The most frequent acute tox-
icities were mild headaches and nausea. 
No acute grade 2 or higher toxicity was 
observed.
Discussion
In patients with limited brain metastases, 
the positive effects of WBRT in decreas-
ing the rate of intracranial progression do 
not translate into survival or quality of life 
benefits [22]. Up until now, no prospec-
tive study including a quality of life as-
sessment has investigated stereotactic ir-
radiation of the resection cavity as an al-
ternative to upfront WBRT after surgery. 
In light of these findings, it is our prac-
tice to omit or defer WBRT in favor of 
SRS or SHRT in postoperative patients 
with a limited number of brain metasta-
ses. In our study, the LC rates after 6 and 
12 months were 91 and 77%, respectively, 
with a median follow-up of 9.6 months. 
These results are comparable to the LC 
rates of 75–90% achieved previously with 
adjuvant WBRT [17].
Frameless image-guided 
SRS and SHRT
Noninvasive patient immobilization and 
frameless image guidance as applied in 
SRS of brain metastases are techniques 
that have been recently introduced. A 
number of reports regarding the accura-
cy of image-guided methods have demon-
strated that submillimeter accuracies can 
be achieved and that accuracy is compa-
rable to the traditional frame-based ap-
proach [5, 9]. In our experience, mean pa-
tient setup errors for the SRS and SHRT 
treatments were comparable to published 
reports. The number of reports explor-
ing the efficacy and morbidity associat-
ed with frameless image-guided SRS and 
SHRT of the resection cavity is limited 
([6, 11, 18, 21, 23, 25, 26], . Tab. 3). The 
SRS studies suggest that LC rates of 74–
89% can be obtained using a radiosurgical 
Tab. 3 Summary of published frameless image-guided series
Author Tech-
nique
No. 
 cavities
Follow- 
up 
(months, 
median)
Dose  
(Gy, me-
dian)
Margins Local 
control 
(%)
Median 
OS 
(months)
Soltys et 
al. [23]
CK 72 8.1 18.6 No 
 margina
86 15.1
Rwigema 
et al. [21]
CK 77 13.8 18 1 mm 74 14.5
Choi et al. 
[6]
CK 120 11 20 
(1–5 frac-
tions)
2 mm 89 17
Wang et 
al. [26]
CK 37 5.5 3×8 Gy 2–3 mm 80 5.5
Prabhu et 
al. [18]
LINAC 64 9.7 18 2 mm 83 13.4
Kelly et al. 
[11]
LINAC 18 12.7 18 No 
 margin
89 Not 
reached
Stein-
mann et 
al. [25]
LINAC 33 10.7 10×4 Gy
7×5 Gy
5×6 Gy
4 mm 76 20.2
Present 
study
LINAC 44 9.6 17
10×4 Gy
4×6 Gy
6×4 Gy
3 mm 77 15.9
OS overall survival, CK Cyberknife® (Accuray, Sunnyvale, CA, USA), LINAC linear accelerator. aOnly a minority of 
cases with 2-mm margins.
Tab. 4 Patient setup accuracy
  Lat.  
(mm)
Long. 
(mm)
Vert.  
(mm)
Pitch  
(°)
Roll  
(°) 
Rotation 
(°)
SRS mean
(SD)
−0.03
(0.25)
0.00
(0.36)
0.01
(0.26)
0.13
(0.27)
0.00
(0.25)
0.03
(0.24)
SHRT mean
(SD)
0.05
(0.32)
0.00
(0.38)
−0.05
(0.30)
−0.06
(0.35)
0.02
(0.24)
−0.05
(0.26)
SRS stereotactic radiosurgery, SHRT stereotactic hypofractionated radiotherapy, SD standard deviation, lat lat-
eral axis, long longitudinal axis, vert vertical axis, pitch angulation to lateral axis, roll angulation to longitudinal 
axis, rotation angulation to vertical axis.
Tab. 2 Characteristics of patients with a local recurrence
Patient no. 1 2 3 4
Primary tumor Esophageal 
cancer
Rectal cancer Melanoma Rectal cancer
Dose (Gy) 6×4 Gy 1×17 Gy 10×4 Gy 4×6 Gy
Resection status R0a, piecemeal R0a, piecemeal R0a, piecemeal R0a, piecemeal
PTV size (cm3) 25.8 8.1 30 16.5
Time to recur-
rence (months)
8.7 6 9 3.5
Salvage treat-
ment
WBRT SRS Surgery + SRS Surgery + WBRT
WBRT whole brain radiation therapy, SRS stereotactic radiosurgery, PTV planning target volume. aR0 status was 
assessed by postoperative MRI.
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dose of 18 Gy [12, 18, 21, 23]. However, the 
SRS dose to the resection cavity in the ab-
sence of WBRT remains a topic of inves-
tigation. In multivariate analysis, smaller 
PTV volumes and marginal doses <18 Gy 
were predictive for reduced LC [18]. In 
our analysis, we observed only a single re-
currence in the SRS group, with a dose of 
17 Gy and a PTV volume of 11.1 cm3. The 
SHRT studies suggest that LC rates of 76–
89% can be obtained using regimens of 
3–10 fractions with total doses ranging 
from 20 to 40 Gy [6, 25, 26]. However, it 
is difficult to compare the results of these 
studies due to the large hetereogeneity of 
the fractionation regimens. A recent re-
port comparing different dose concepts 
in SHRT showed that EQD2s of ≥35 Gy 
seem to be the most effective concept in 
patients with primary or recurrent limited 
primary brain metastases [14]. We com-
pared SRS to different hypofractionated 
regimens and failed to find any fraction-
ation-associated differences in LC due to 
the high diversity of dose concepts. How-
ever, in our study the LC rate in the SHRT 
group was 60% and in 2 out 3 patients 
with recurrence, the EQD2 was <35 Gy.
The importance of other key issues, 
such as target volume definition and the 
use of margins, also has to be established.
Target volume
At present, there are no well established 
guidelines concerning the definition of 
the target after surgical resection of brain 
metastases. There are no prospective da-
ta showing that the inclusion of the surgi-
cal track has an impact on LC. However, 
surgical resection seems to be crucial in 
terms of local recurrence incidence rates. 
Patel and colleagues reported that resec-
tion of the tumor in a piecemeal fashion 
significantly increased the incidence of lo-
cal recurrence in comparison with en bloc 
resection [17]. The resection of metastat-
ic lesions in contact with or involved with 
the cerebrospinal fluid (CSF) pathway is 
associated with a significantly higher inci-
dence of leptomeningeal seeding than re-
section of tumors separated from the CSF 
pathway by brain parenchyma [1]. The ad-
dition of margins around the surgical cav-
ity remains controversial. Neuropatho-
logical studies have shown that infiltra-
tion may be responsible for the presence 
of clinically undetectable cancer islands 
showing a maximum infiltration depth of 
1–3 mm [2].
Toxicity
Choi and colleagues reported the first pro-
spective data showing that the addition of 
a 2-mm margin to the resection cavity re-
sulted in a decreased local failure rate at 
12 months from 16 to 3%, without increas-
ing toxicity [6]. In our series, we observed 
symptomatic and pathologically prov-
1.0
0.8
0.6
0.4
0.2
0.0
0 5 10 15 20 25
time (months)
pr
op
or
tio
n 
re
m
ai
ni
ng
 e
ve
nt
-f
re
e
a
1.0
0.8
0.6
0.4
0.2
0.0
0 5 10 15 20 25
time (months)
pr
op
or
tio
n 
re
m
ai
ni
ng
 e
ve
nt
-f
re
e
SRS
SHRT
p=0.15
b
Fig. 1 9 Local control. a All 
patients, b patients strati-
fied by treatment. SRS ste-
reotactic radiosurgery (sol-
id line in b), SHRT stereo-
tactic hypofractionated ra-
diotherapy (dotted line 
in b)
1.0
0.8
0.6
0.4
0.2
0.0
0 5 10 15
time (months)
pr
op
or
tio
n 
re
m
ai
ni
ng
 e
ve
nt
-f
re
e
20 25 30
Fig. 2 9 Overall surviv-
al of all patients
769Strahlentherapie und Onkologie 9 · 2013  | 
en radionecrosis in 1 patient treated by a 
single fraction of 17 Gy. Clinical data on 
the toxicity profile of postoperative hypo-
fractionated SRS and SHRT remain limit-
ed. Wang and colleagues reported a com-
bined rate of all toxicities (radionecrosis, 
prolonged steroid use and new-onset sei-
zures) of 9% using Cyberknife® (Accuray, 
Sunnyvale, CA, USA) hypofractionated 
SRS with 3 fractions of 8 Gy daily [26]. No 
toxicity grade 2 or higher was reported by 
Steinmann and colleagues using three dif-
ferent fractionation concepts with SHRT 
to the resection cavity [25]. For most le-
sions, 40 Gy in 10 fractions was applied 
according to the guidelines reported in 
the previous phase II trial of SHRT, which 
recommended that the V4 Gy per frac-
tion for normal brain should not exceed 
20 cm3 [8]. In our SHRT treated patient 
group, the median normal brain V4 Gy/
fraction was 5.9 cm3 and we did not ob-
serve acute grade 2 or higher toxicity.
Conclusion
Frameless image-guided LINAC-based 
adjuvant SRS and SHRT is a safe and ef-
fective treatment after resection of brain 
metastases in patients with oligometa-
static disease. The system’s accuracy is 
comparable to that of frame-based sys-
tems. In the current study, we found 
SHRT to be comparable to single-fraction 
SRS in terms of local tumor control and 
toxicity. This treatment strategy and its 
correlation with quality of life should be 
explored by additional studies.
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